Chronic thromboembolic pulmonary hypertension risk score evaluation and validation (CTEPH SOLUTION): proposal of a study protocol aimed to realize a validated risk score for early diagnosis.


Journal

Minerva cardiology and angiology
ISSN: 2724-5772
Titre abrégé: Minerva Cardiol Angiol
Pays: Italy
ID NLM: 101776555

Informations de publication

Date de publication:
Oct 2022
Historique:
pubmed: 12 3 2021
medline: 24 9 2022
entrez: 11 3 2021
Statut: ppublish

Résumé

Chronic thromboembolic pulmonary hypertension (CTEPH) is the most serious long-term complication of acute pulmonary embolism (PE) though it is the only potentially reversible form of pulmonary hypertension (PH). Its incidence is mainly limited to the first 2 years following the embolic event, however it is often underdiagnosed or misdiagnosed. This is a multicenter observational cross-sectional and prospective study. Patients with a prior diagnosis of PE will be enrolled and undergo baseline evaluation for prevalent PH detection through a clinical examination and an echocardiogram as first screening exam. All cases of intermediate-high echocardiographic probability of PH will be confirmed by right heart catheterization and then identified as CTEPH through appropriate imaging and functional examinations in order to exclude other causes of PH. A CTEPH Risk Score will be created using retrospective data from this prevalent cohort of patients and will be then validated on an incident cohort of patients with acute PE. One thousand retrospective and 218 prospective patients are expected to be enrolled and the study is expected to be completed by the end of 2021. Up to now 841 patients (620 retrospective and 221 prospective) have been enrolled. This study is the first large prospective study for the prediction of CTEPH development in patients with PE. It aims to create a comprehensive scoring tool that includes echocardiographic data which may allow early detection of CTEPH and the application of targeted follow-up screening programs in patients with PE.

Sections du résumé

BACKGROUND BACKGROUND
Chronic thromboembolic pulmonary hypertension (CTEPH) is the most serious long-term complication of acute pulmonary embolism (PE) though it is the only potentially reversible form of pulmonary hypertension (PH). Its incidence is mainly limited to the first 2 years following the embolic event, however it is often underdiagnosed or misdiagnosed.
METHODS METHODS
This is a multicenter observational cross-sectional and prospective study. Patients with a prior diagnosis of PE will be enrolled and undergo baseline evaluation for prevalent PH detection through a clinical examination and an echocardiogram as first screening exam. All cases of intermediate-high echocardiographic probability of PH will be confirmed by right heart catheterization and then identified as CTEPH through appropriate imaging and functional examinations in order to exclude other causes of PH. A CTEPH Risk Score will be created using retrospective data from this prevalent cohort of patients and will be then validated on an incident cohort of patients with acute PE.
RESULTS RESULTS
One thousand retrospective and 218 prospective patients are expected to be enrolled and the study is expected to be completed by the end of 2021. Up to now 841 patients (620 retrospective and 221 prospective) have been enrolled.
CONCLUSIONS CONCLUSIONS
This study is the first large prospective study for the prediction of CTEPH development in patients with PE. It aims to create a comprehensive scoring tool that includes echocardiographic data which may allow early detection of CTEPH and the application of targeted follow-up screening programs in patients with PE.

Identifiants

pubmed: 33703863
pii: S2724-5683.21.05575-7
doi: 10.23736/S2724-5683.21.05575-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

545-554

Auteurs

Cristiano Miotti (C)

Department of Cardiovascular and Respiratory Sciences, Sapienza University, Rome, Italy.

Andrea M D'Armini (AM)

Section of Cardiac Surgery, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, San Matteo Polyclinic Hospital, Pavia, Italy.

Beatrice Scardovi (B)

Unit of Cardiology, Santo Spirito in Saxia Hospital, Rome, Italy.

Stefano Ghio (S)

S. Matteo Plyclinic Hospital, Pavia, Italy.

Gianfranco Sinagra (G)

Department of Cardiovascular Surgery, Ospedali Riuniti Hospital, Trieste, Italy.

Walter Serra (W)

Unit of Cardiology, Maggiore Hospital, AOU Parma, Parma, Italy.

Antonella Romaniello (A)

Unit of Cardiology, Sant'Andrea Hospital, Rome, Italy.

Giuseppe Galgano (G)

Unit of Cardiology and Intensive Care, Francesco Miulli Regional Hospital, Acquaviva delle Fonti, Bari, Italy.

Loris Roncon (L)

Division of Cardiology, ULSS 18 Rovigo, Santa Maria della Misericordia Hospital, Rovigo, Italy.

Michele D'Alto (M)

Department of Cardiology, Monaldi Hospital, L. Vanvitelli University, Naples, Italy.

Daniela Giannazzo (D)

Division of Cardiology, Ferrarotto Hospital, AOU Policlinico Vittorio Emanuele, Catania, Italy.

Patrizio Vitulo (P)

Department of Pneumology, Mediterranean Institute of Trasplantation and Highly-Specialized Therapetics (ISMETT), Palermo, Italy.

Amedeo Bongarzoni (A)

Department of Cardiology, San Carlo Borromeo Hospital, Milan, Italy.

Matteo Ruzzolini (M)

Unit of Cardiology and Intensiva Care, San Giovanni Calibita Fatebenefratelli Hospital, Rome, Italy.

Carlo Albera (C)

Service of Pneumology, Molinette Hospital, Turin, Italy.

Gavino Casu (G)

Unit of Cardiology, San Francesco Hospital, Nuoro, Italy.

Martina Perazzolo Marra (M)

Department of Cardiologic, Thoracic, and Vascular Sciences, AOU Padua, Padua, Italy.

Sante D Pierdomenico (SD)

Unit of Cardiovascular Diseases, Department of Medical and Oral Sciences and Biotechnologies, G. d'Annunzio University, Chieti, Italy.

Federico Luongo (F)

Department of Cardiovascular and Respiratory Sciences, Sapienza University, Rome, Italy.

Giovanna Manzi (G)

Department of Cardiovascular and Respiratory Sciences, Sapienza University, Rome, Italy.

Silvia Papa (S)

Department of Cardiovascular and Respiratory Sciences, Sapienza University, Rome, Italy.

Gianmarco Scoccia (G)

Department of Cardiovascular and Respiratory Sciences, Sapienza University, Rome, Italy.

Nadia Cedrone (N)

Department of Cardiovascular and Respiratory Sciences, Sapienza University, Rome, Italy.

Roberto Badagliacca (R)

Department of Cardiovascular and Respiratory Sciences, Sapienza University, Rome, Italy.

Carmine D Vizza (CD)

Department of Cardiovascular and Respiratory Sciences, Sapienza University, Rome, Italy - dario.vizza@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH